Reports atypical neurofibromatous neoplasms in children, indicating importance of early detection.
Atypical neurofibromatous neoplasm of uncertain biological potential (ANNUBP) lies between plexiform neurofibroma and malignant peripheral nerve sheath tumor (MPNST) in neurofibromatosis type 1 (NF1). Pediatric data are limited. We report two children with NF1 and rapidly enlarging peripheral nodules. Patient 1: a 13-year-old boy developed a lumbogluteal nodule despite prior selumetinib. Ultrasound showed a hypoechoic lesion with vascularity; magnetic resonance imaging confirmed interval growth. Excision revealed hypercellularity, architectural loss, cytologic atypia, and up to 2 mitotic figures/10 high-power fields. Immunohistochemistry showed S100/SOX10 positivity, focal CD34 loss, p16 loss, p53 wild-type pattern, and Ki-67 ≈1% overall, consistent with ANNUBP. Patient 2: a 15-year-old girl had a painful mass on the volar forearm. Resection disclosed a tumor embedded with a median-nerve fascicle. Histology showed hypercellularity, architectural loss, and 1 mitotic figure/10 high-power fields without necrosis; Immunohistochemistry showed S100, focal CD34/p16 reduction, and Ki-67 < 1%. Both patients remain recurrence-free under risk-adapted surveillance. ANNUBP is defined by ≥2 of atypia, hypercellularity, architectural loss, and low-level mitotic figures. Frameworks integrate morphology with CDKN2A/B and emphasize retained H3K27me3 to distinguish ANNUBP from MPNST. In children, ultrasound, magnetic resonance imaging, and positron emission tomograph support triage and biopsy. When feasible, complete excision is preferred; unresectable lesions need closer imaging. Early recognition widens cure opportunities and may refine risk stratification.
No takes yet. Share an insight, caveat, or question.
Román-Mendoza et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: